Critical Contrast: OPKO Health (NASDAQ:OPK) vs. LifeMD (NASDAQ:LFMD)

LifeMD (NASDAQ:LFMD) and OPKO Health (NASDAQ:OPK) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, earnings, institutional ownership and dividends.

Insider & Institutional Ownership

35.5% of LifeMD shares are owned by institutional investors. Comparatively, 64.6% of OPKO Health shares are owned by institutional investors. 17.2% of LifeMD shares are owned by company insiders. Comparatively, 44.7% of OPKO Health shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Risk and Volatility

LifeMD has a beta of 2.19, suggesting that its stock price is 119% more volatile than the S&P 500. Comparatively, OPKO Health has a beta of 1.52, suggesting that its stock price is 52% more volatile than the S&P 500.

Valuation & Earnings

This table compares LifeMD and OPKO Health”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LifeMD	$191.59 million	0.43	$14.35 million	($0.05)	-34.30
OPKO Health	$606.90 million	2.10	-$225.68 million	($0.19)	-9.03

LifeMD has higher earnings, but lower revenue than OPKO Health. LifeMD is trading at a lower price-to-earnings ratio than OPKO Health, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares LifeMD and OPKO Health’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
LifeMD	0.10%	-168.23%	-31.27%
OPKO Health	-29.51%	-10.90%	-6.93%

Analyst Recommendations

This is a breakdown of current ratings and price targets for LifeMD and OPKO Health, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LifeMD	1	1	8	0	2.70
OPKO Health	1	2	4	0	2.43

LifeMD currently has a consensus target price of $7.57, suggesting a potential upside of 341.48%. OPKO Health has a consensus target price of $3.42, suggesting a potential upside of 99.22%. Given LifeMD’s stronger consensus rating and higher possible upside, analysts clearly believe LifeMD is more favorable than OPKO Health.

About LifeMD

LifeMD, Inc. is a direct-to-consumer telehealth company that provides virtual medical care, prescription treatments and related health services through its digital platform. The company connects patients with licensed health care providers for online consultations, ongoing care and, when clinically appropriate, prescription medications. Its services include virtual primary care and programs focused on areas such as weight management, men’s health, women’s health, dermatology and chronic-care support.

About OPKO Health

OPKO Health is a healthcare company with businesses in diagnostics and pharmaceuticals. Its diagnostic offerings have included BioReference Health laboratory services and the 4Kscore test, which helps assess the risk of aggressive prostate cancer. OPKO’s pharmaceutical products include Rayaldee, a prescription treatment for certain adults with chronic kidney disease and vitamin D insufficiency. The company also co-developed NGENLA, a long-acting growth hormone treatment for children with growth hormone deficiency, with Pfizer.